ScholarIQanswers from OpenAlex

Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes

PaperCitations, authors & open-access status

Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes have?

ScholarIQcitation count

Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes has 45 citations in the OpenAlex counts ScholarIQ stores.

When was Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes published?

ScholarIQyear

Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes has 2021 year in the ScholarIQ index.

What is the open-access status of Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes?

ScholarIQoa status

Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes has closed oa status in the ScholarIQ index.

What is the DOI of Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes?

ScholarIQdoi

The DOI for Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes is on the source record.

What is the PMID of Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes?

ScholarIQpmid

The PMID for Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes is on the source record.

What is the OpenAlex record for Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes?

ScholarIQopenalex

The OpenAlex for Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial